95 related articles for article (PubMed ID: 22884159)
1. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
Sun FK; He HC; Su TW; Zhou WL; Huang X; Dai J; Shen ZJ
Chin Med J (Engl); 2012 Jun; 125(12):2231-4. PubMed ID: 22884159
[TBL] [Abstract][Full Text] [Related]
2. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.
Park KS; Lee JL; Ahn H; Koh JM; Park I; Choi JS; Kim YR; Park TS; Ahn JH; Lee DH; Kim TW; Lee JS
Jpn J Clin Oncol; 2009 May; 39(5):327-31. PubMed ID: 19264767
[TBL] [Abstract][Full Text] [Related]
4. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
[TBL] [Abstract][Full Text] [Related]
5. [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Kukla U; Łabuzek K; Chronowska J; Bobrzyk M; Madej P; Okopień B
Pol Merkur Lekarski; 2015 Apr; 38(226):191-5. PubMed ID: 25938384
[TBL] [Abstract][Full Text] [Related]
6. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib treatment for refractory malignant pheochromocytoma.
Nemoto K; Miura T; Shioji G; Tsuboi N
Neuro Endocrinol Lett; 2012; 33(3):260-4. PubMed ID: 22635080
[TBL] [Abstract][Full Text] [Related]
8. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib for refractory malignant pheochromocytoma: two case reports.
Hata J; Haga N; Ishibashi K; Takahashi N; Ogawa S; Kataoka M; Akaihata H; Satoh Y; Koguchi T; Kojima Y
Int Urol Nephrol; 2014 Jul; 46(7):1309-12. PubMed ID: 24510251
[TBL] [Abstract][Full Text] [Related]
10. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
[No Abstract] [Full Text] [Related]
11. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
13. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
14. Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib.
Droege F; Thangavelu K; Lang S; Geisthoff U
Ann Hematol; 2016 Dec; 95(12):2077-2078. PubMed ID: 27525726
[No Abstract] [Full Text] [Related]
15. Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
Mauri D; Panou C; Valachis A; Kamposioras K; Tsali L
Exp Oncol; 2009 Mar; 31(1):60-1. PubMed ID: 19300420
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
17. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Addeo R; Caraglia M
Expert Rev Anticancer Ther; 2011 Feb; 11(2):139-42. PubMed ID: 21342029
[No Abstract] [Full Text] [Related]
18. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Maksimovic O; Schraml C; Hartmann JT; Bitzer M; Claussen CD; Pintoffl J; Horger M
AJR Am J Roentgenol; 2010 Jan; 194(1):5-14. PubMed ID: 20028898
[TBL] [Abstract][Full Text] [Related]
20. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
